90-Second Read: New dual-strike pill aims to tackle deadly Ebola and Hantavirus outbreaks

Dual-strike antiviral targets Hantavirus, Ebola and Lassa, as Traws advances non-clinical development and scales manufacturing for outbreak response. Traws Pharma (NASDAQ:TRAW) is advancing a proprietary broad-spectrum antiviral combination targeting ongoing Hantavirus, Ebola and potential Lassa outbreaks. This announcement details advancement of a novel dual-strike broad-spectrum antiviral candidate targeting Hantavirus, Ebola and Lassa, including planned work in BSL-3 and BSL-4 labs and engagement with agencies such as the CDC, NAFDAC and AMA. The agent uses a novel dual-strike, host-targeted mechanism to deplete cellular nucleotides and force viral use of nucleoside mimics.

Over the past six months, TRAW has highlighted financing and pipeline progress, including an up to $60 million private placement and ongoing development of tivoxavir marboxil, ratutrelvir and Hantavirus candidates. News on May 8 about advancing Hantavirus clinical candidates and the May 15 Q1 2026 update both saw positive price reactions. Recognizing the critical importance of regional healthcare organizations and rapid deployment, Traws Pharma will build on existing contacts in Nigeria, in particular its relationship with the NAFDAC to develop sustainable, local manufacturing of drug products. According to Traws Pharma, both components have prior human safety data as single agents.

TRAW is up 6.04% while momentum-screened peers show mixed moves: PHGE down 20.35%, XTLB up 3.36%, and BCTX up 5.26%. Earlier, a Feb 19 clinical analysis and regulatory setbacks drew a sharp selloff. An effective Form S-3 shelf dated May 8, 2026 registers up to 35,897,514 shares for resale by selling stockholders. The investigational combination utilizes a unique "dual-strike" mechanism of action that hijacks host cell pathways to force viral eradication.

Recent TRAW news often triggered sizable moves, with pipeline and financing updates generally aligning with price direction; one full-year results event saw a mild negative reaction despite positive strategic developments. It extends Traws' recent focus on emerging viral threats. Traws would not receive proceeds from these resales, only potential cash if associated warrants are exercised for cash.